Toxoplasma gondii (T. gondii) (T. gondii)

Toxoplasma gondii is an obligate intracellular protozoan parasite within the phylum Apicomplexa and is the causative agent of toxoplasmosis, a common infection that affects approximately one-third of the global population [1]. In humans, infection occurs primarily through the ingestion of oocysts from contaminated environments or tissue cysts in undercooked meat, leading to a persistent, lifelong infection marked by dormant cysts in the central nervous system and muscle tissue [2]. While often asymptomatic in healthy individuals, the parasite poses severe risks to immunocompromised patients, such as those with HIV/AIDS, where it can cause life-threatening encephalitis [3]. Furthermore, congenital transmission during pregnancy can lead to significant fetal complications, including hydrocephalus and chorioretinitis [4]. Therapeutic strategies against T. gondii do not target a single receptor but rather essential parasitic enzymes; the current standard of care involves the combination of pyrimethamine and sulfadiazine, which inhibits the parasite's folate synthesis pathway [5]. Other interventions include atovaquone, which targets the mitochondrial cytochrome bc1 complex to disrupt energy production within the organism [1][6]. Sources: [1] CDC Toxoplasmosis Resources (2024); [2] Hill & Dubey, 'Toxoplasma gondii: transmission, diagnosis and prevention' (2002); [3] NIH AIDSinfo Guidelines (2023); [4] Mayo Clinic Toxoplasmosis Overview (2023); [5] StatPearls: Toxoplasmosis (2023); [6] PubChem Compound Summary: Atovaquone (2024).

Other names

T. gondiiToxoplasmosis parasiteApicomplexan parasite

Drugs targeting this organism typically inhibit essential metabolic pathways such as folic acid synthesis via the inhibition of dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), disrupt mitochondrial respiration through the cytochrome bc1 complex, or inhibit protein synthesis at the ribosomal level [1][3].